Article

Anti-suppressor effect of cyclophosphamide on the development of spontaneous diabetes in NOD mice.

INSERM U 25-CNRS UA 122-Hôpital, Necker, Paris.
European Journal of Immunology (Impact Factor: 4.97). 04/1988; 18(3):481-4. DOI: 10.1002/eji.1830180325
Source: PubMed

ABSTRACT In the NOD mouse, an autoimmune process beginning by 5 weeks of age with lymphocyte infiltration and destruction of insulin-secreting beta cells leads to overt diabetes which begins to appear by 11 weeks of age. Although there is a high incidence of insulitis by 10 weeks of age (greater than 80%) in both males and females, by 30 weeks of age diabetic symptoms have occurred in 53-80% of females and in 12-40% of males. Intraperitoneal injection of a high dose (200 mg/kg) of cyclophosphamide (CY) consistently induces the onset of diabetes in male and female NOD mice at an age when spontaneous diabetes rarely occurs. Spleen T cells from CY-induced diabetic mice are capable of transferring the disease into irradiated nondiabetic syngeneic recipients. This indicates that the diabetogenic effect of CY is not mediated by direct toxicity on pancreatic beta cells but is mediated by abrogation of a suppressor mechanism which may prevent activation of T cells responsible for the development of diabetes in the NOD mouse. Additionally, CY is only effective in NOD mice and not in F1 hybrids between NOD and other strains of mice. Thus, the potential beta cell aggressor mechanism is not present in these hybrids as it is in homozygous mice, which indicates that it is not under the control of dominant genes.

0 Bookmarks
 · 
65 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Acinetobacter baumannii is an opportunistic Gram-negative bacterium that affects critically ill hospitalized patients with breaches in skin integrity and airway protection leading to significant morbidity and mortality. Considering the paucity of well-established animal models of immunosuppression to study A. baumannii pathogenesis, we set out to characterize a murine model of immunosuppression using the alkylating agent cyclophosphamide (CYP). We hypothesize that CYP-induced immunosuppression would increase the susceptibility of C57BL/6 to develop A. baumannii-mediated pneumonia followed by systemic disease. We demonstrated that CYP intensified A. baumannii-mediated pulmonary disease, abrogated normal immune cell function and lead to altered pro-inflammatory cytokine release. The development of an animal model that mimics A. baumannii infection onset in immunosuppressed individuals is crucial for generating novel approaches to patient care and improving public health strategies to decrease susceptibility of infection for individuals at risk.
    Journal of Medical Microbiology 09/2013; · 2.30 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A CO2 reforming catalyst and process have been developed. The commercial scale CO2 reforming catalyst has demonstrated its activity and stability in pilot plant tests under operating conditions for the manufacture of synthesis gas with a H2/CO ratio of 2.0 for approximately 7,000 hours. In these tests, synthesis gas was generated by CO2 and H2O reforming with high energy efficiency: low CO2/carbon and low H2O/carbon ratios in feed gas composition. Our catalyst exhibited high carbon removal characteristics with steam from the catalyst surface, which prevents carbon deposition on our CO2 reforming catalyst.
    Studies in Surface Science and Catalysis - STUD SURF SCI CATAL. 01/2007; 167:385-390.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The corticosteroid-sparing immunosuppressive agents commonly used in dermatology include azathioprine, cyclophosphamide, methotrexate and cyclosporin. The pharmacology, use and adverse effects of these agents are reviewed. Azathioprine is an antimetabolite whose immunosuppressive effects involve mainly suppression of cellular cytotoxicity and to a lesser degree antibody responses. The role of genetic polymorphisms in its metabolism and efficacy and in the incidence of adverse effects is increasingly being recognised. Cyclophosphamide is an antimetabolite that has potent B cell inhibitory effects as well as a differential effect on subsets of macrophages. Its immunosuppressive effect is of more rapid onset than that of azathioprine. Intravenous pulse administration of cyclophosphamide is becoming more popular in an effort to decrease the overall dosage and toxicity. The immunomodulatory role of methotrexate is being more fully appreciated, as is the role of rescue therapy with folic and folinic acids in reducing haematological and gastrointestinal toxicity. Hepatotoxicity remains a major concern with methotrexate, and its use in renal insufficiency requires dosage modification. Cyclosporin has potent and well-defined T cell inhibitory effects, and its role is being expanded in inflammatory dermatoses. Cumulative renal toxicity currently limits its use. Recent clinical data on the use of these agents in blistering disorders, connective tissue diseases (systemic lupus erythematosus, cutaneous lupus erythematosus, dermatomyositis and scleroderma), eczematous disorders (chronic actinic dermatitis, severe chronic atopic dermatitis), vasculitides (Behçet’s disease and Wegener’s granulomatosis) and psoriasis are reviewed in a comparative manner. Azathioprine and cyclophosphamide have a major role in the treatment of autoantibody-mediated inflammatory skin disease. Cyclosporin and methotrexate have a greater role in primarily T cell—mediated inflammatory cutaneous disease.
    Clinical Immunotherapeutics. 04/1996; 5(4).